Beating the odds of reherniation

Click here to register for a future webinar session.

The Barricaid Annular Closure Device is designed to prevent lumbar reherniation, leading to fewer reoperations and readmissions, and thereby helping to alleviate an unnecessary burden on the healthcare system.
A 30 minute weekly live educational webinar and Q&A by Founder Greg Lambrecht and Head of Research & Development Oscar Yeh, including:

• Unmet clinical need
• Barricaid design rationale

• Level I clinical results
• Q&A session

Greg Lambrecht
Founder & Executive Director

A trained scientist & experienced medical entrepreneur, Greg founded Intrinsic Therapeutics 20 years ago to deliver herniated disc patients like his mother a better solution.

Oscar Yeh, PhD
Vice President, Research & Development

Having evaluated Barricaid from the preclinical phase, Oscar has driven research efforts culminating in over 40 published papers on Randomized Clinical Trial data and FDA PMA approval.

For complete risk-benefit information:

If Barricaid is right for you, we can help.

Sign up to receive future updates and information on the Barricaid procedure.
  • This field is for validation purposes and should be left unchanged.

WordPress Lightbox Plugin